Washington, DC 20549




Form 6-K







For the month of June 2017

Commission File Number 001-37846





(Translation of registrant’s name into English)




23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive office)




Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.


Form 20-F    x                Form 40-F    ¨


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨


Note :  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨


Note :  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.





Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “Cellect Receives Notice of Allowance from the US Patent & Trademark Office.”




99.1 Press Release, dated June 12, 2017






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



  Cellect Biotechnology Ltd.
  By: /s/ Eyal Leibovitz  
  Name:   Eyal Leibovitz  
Date: June 12, 2017 Title: Chief Financial Officer  





Exhibit 99.1


Cellect Receives Notice of Allowance

from the US Patent & Trademark Office


Patent Covers

Any Device Using Cellect’s Flagship Technology – the ApoGraft™





Devices using ApoGraft™ are intended for use in a wide range of applications including Bone Marrow Transplants and other immune related medical conditions such as Diabetes type I, inflammatory bowel disease, etc


T el Aviv, Israel – June 12th, 2017 Cellect Biotechnology Ltd. (Nasdaq: APOP , TASE: APOP), a developer of stem cells isolation technology, announced today that it has received a formal notice of allowance for a patent (Application No. 14/383,288) covering a key composition of matter and method of use. Similar to the patents granted previously, the current patent significantly enhances Cellect’s protection of its core technology and its commercial applications by covering the various devices using the ApoGraft for selection of stem cells.


The device is designed to enable single step cell selection in a simplified setting by an off-the-shelf product - a solution that currently does not exist and covering a wide range of unmet medical needs.


The devices covered by the patent are essentially containers (a bag, column, tube, bottle, vial, flask or bioreactor) comprised of a biocompatible material and a biologically active apoptosis-inducing ligand immobilized to a surface in the inner side of the container. The device is adapted to cell selection of apoptosis-sensitive cells. Specifically, the patent is expected to give the Company full protection against any devices that make use of apoptosis for cell selection and is also expect to protect the method for using the device. 


Such devices, if successfully developed and approved, may enable selection of stem-cells and are expected to reduce fatal inflammatory responses such as graft versus host disease (GvHD) associated with stem cell transplantations.


Dr. Shai Yarkoni, CEO, commented, “This patent is a fundamental base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, we believe that Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments.”


About Cellect Biotechnology Ltd.


Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a novel technology designed to isolate stem cells from any given tissue, a technology that aims to improve a variety of stem cells applications.


The Company’s technology is intended to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. Cellect’s technology may be applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.





Forward Looking Statements

This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our expectation that a patent will be issued based on pending patent applications, our beliefs about the future integration of our technology into the production procedures of stem cell-based products, the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov. and in the Company’s periodic filings with the SEC and the Tel-Aviv Stock Exchange.



Cellect Biotechnology Ltd.

Eyal Leibovitz, Chief Financial Officer


+ 972-9-974-1444